<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431028</url>
  </required_header>
  <id_info>
    <org_study_id>Duocat 001</org_study_id>
    <nct_id>NCT00431028</nct_id>
  </id_info>
  <brief_title>Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery</brief_title>
  <official_title>Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare one intraoperative sub-Tenon's capsule injection of&#xD;
      triamcinolone and ciprofloxacin in a biodegradable controlled-release system with&#xD;
      conventional prednisolone and ciprofloxacin eye drops to treat ocular inflammation and for&#xD;
      infection prophylaxis after cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical steroids effectively control ocular inflammation, but are associated with the&#xD;
      well-recognized problems of patient compliance. Injection of depot corticosteroids into&#xD;
      sub-Tenon's capsule is an established method of treating various ocular inflammatory&#xD;
      diseases. Its prolonged therapeutic effect has provided the ophthalmologist with an&#xD;
      alternative tool for the treatment of different diseases that may be extended to the surgical&#xD;
      arena to modulate postoperative inflammation.&#xD;
&#xD;
      The use of topical antibiotic agents poses unique and challenging hurdles for drug delivery,&#xD;
      especially because recent reports have suggested that the incidence of endophthalmitis may be&#xD;
      increasing. Exploiting the permeability of the sclera, subconjunctival routes may offer a&#xD;
      more promising alternative for enhanced drug delivery and tissue targeting compared with&#xD;
      topical routes. In theory, the combination of an antibiotic with a steroid in a&#xD;
      controlled-release system delivered transscleral could be feasible after cataract surgery to&#xD;
      achieve several clinical objectives, i.e., eliminate topical medications, enhance patient&#xD;
      compliance, improve drug bioavailability, and protect the patient from infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated&#xD;
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior chamber cell</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior chamber flare</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lack of anti-inflammatory response</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of infection</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia</measure>
    <time_frame>Days 1, 3, 7, 14, and 28 after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle corrected visual acuity</measure>
    <time_frame>Day 28 after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Inflammation</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>colirio</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>slow delivery ciprofloxacin + triamcinolone</intervention_name>
    <description>2 mg ciprofloxacin + 25mg triamcinolone</description>
    <arm_group_label>colirio</arm_group_label>
    <other_name>ciprofloxacin</other_name>
    <other_name>triamcinolona</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with uncomplicated, senile cataract&#xD;
&#xD;
          -  Best-corrected visual acuity (VA) of 20/100 or better in the fellow eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in use of oral or topical anti-inflammatory agents&#xD;
&#xD;
          -  History of steroid-induced ocular hypertension&#xD;
&#xD;
          -  Hypermature cataracts&#xD;
&#xD;
          -  Previous ocular surgery&#xD;
&#xD;
          -  Preexisting uveitis&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Corneal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Paganelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>March 6, 2008</last_update_submitted>
  <last_update_submitted_qc>March 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>fernando paganelli</name_title>
    <organization>federal university of sao paulo</organization>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Endophthalmitis</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Drug Delivery Systems</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

